-

Concert Pharmaceuticals to Webcast Presentation at UBS Virtual Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the 2020 UBS Virtual Global Healthcare Conference on May 19, 2020 at 3:00 p.m. ET.

A live webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Contacts

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com

Concert Pharmaceuticals, Inc.

NASDAQ:CNCE

Release Summary
Concert will present a corporate overview at the 2020 UBS Virtual Global Healthcare Conference on May 19, 2020 at 3:00 p.m. ET.
Release Versions
$Cashtags

Contacts

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com

Social Media Profiles
More News From Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert maintains deuruxolitinib breakthrough therapy designation from FDA for the treatment of alopecia areata....

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

MUMBAI & LEXINGTON, Mass.--(BUSINESS WIRE)--Sun Pharma to acquire Concert Pharmaceuticals....

Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research

MELBOURNE, Australia--(BUSINESS WIRE)--The presentation includes new analyses on the effect of baseline severity and duration of current episode of hair loss on scalp hair regrowth....
Back to Newsroom